Eisai R&d Management Co., Ltd.

Yoichi Kita

Kunitoshi Takeda

Takafumi Motoki

Mamoru Takaishi

Yuichi Suzuki

Tasuku Ishida

Paschalis Dimopoulos

Toshihiko Kaneko

Afzal Khan

Noboru Yamamoto

Toru Watanabe

Toshiaki Tanaka

Makoto Kotake

Yu Yoshida

Keiichi Sorimachi

Kogyoku Shin

Takashi Kosasa

Shinsuke Hirota

Yoshiaki Ohashi

Adrian Hall

Yuji Kazuta

Takahisa Hanada

Yoshihisa Kobayashi

Hiroyuki Higashiyama

Takashi Fukuyama

Tomoyuki Shibuguchi

Yasuaki Kamada

Toshiyuki Ohfusa

Andrew Madin

Yukio Ishikawa

Taro Asaba

Minako Saito

Tetsuyuki Teramoto

Toshiki Kurokawa

Hironori Fukumoto

Nicola Louise Shuker

Provided are compounds represented by the following formulas (I), (II), (III) and (IV) having orexin type 2 receptor-activating activity, or their pharmaceutically acceptable salts. 

Substituted piperidine compounds and their use

Compounds represented by formulae (I) to (XXII) or pharmaceutically acceptable salts thereof: 

Pyranodipyridine compound

Novel indansulfamide derivatives or a pharmaceutically acceptable salt thereof such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, N-[(1S)-2,2,4,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, (+)-N-(2,2,4,6,7-pentafluoro-2,3-dihydro-1H-inden-1-yl)sulfamide, have an action of improving Seizure Severity Index (Score) in mice kindling model. Thus the compounds or the salt thereof are expected as a drug for treating epilepsy.

Indanesulfamide derivatives

A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a Caryl group or the like, L is &#x2014;NRCO&#x2014; or the like (wherein Ris a hydrogen atom or the like), Ring B is a Caryl group or the like, X is a Calkylene group or the like, Y is a single bond or the like, Z is a Calkylene group or the like, Rand Rare each independently a hydrogen atom or the like, and R, R, Rand Rare independently a hydrogen atom, a halogen atom or the like, has an A&#x3b2; production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A&#x3b2; and typified by Alzheimer-type dementia.

Fused aminodihydrothiazine derivatives

The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein

A compound represented by the general formula: wherein Ring A is a Caryl group or the like, L is &#x2014;NRCO&#x2014; or the like (wherein Ris a hydrogen atom or the like), Ring B is a Caryl group or the like, X is a Calkylene group or the like, Y is a Calkylene group or the like, Z is an oxygen atom or the like, Rand Rare each independently a hydrogen atom or the like, and R, R, Rand Rare independently a hydrogen atom, a halogen atom or the like, or a pharmaceutically acceptable salt thereof, or a solvate thereof, has an A&#x3b2; production inhibitory effect or a BACE1 inhibitory effect and is useful as a therapeutic agent for a neurodegenerative disease caused by A&#x3b2; and typified by Alzheimer-type dementia.

Fused aminodihydrothiazine derivative

Growing community of inventors

Tsukuba, Japan

Yoichi Kita